E
Gossamer Bio, Inc.
GOSS
$1.45
$0.1511.54%
E
Sell
12/20/2024Downgrade
Gossamer Bio, Inc. (GOSS) was downgraded to E+ from D- on 12/20/2024 due to a decline in the total return index, valuation index and volatility index.
Gossamer Bio, Inc. (GOSS) was downgraded to E+ from D- on 12/20/2024 due to a decline in the total return index, valuation index and volatility index.
D
Sell
11/27/2024Upgraded
Gossamer Bio, Inc. (GOSS) was upgraded to D- from E+ on 11/27/2024 due to an increase in the valuation index.
Gossamer Bio, Inc. (GOSS) was upgraded to D- from E+ on 11/27/2024 due to an increase in the valuation index.
E
Sell
11/12/2024Downgrade
Gossamer Bio, Inc. (GOSS) was downgraded to E+ from D- on 11/12/2024 due to a major decline in the growth index, solvency index and valuation index. EBIT declined 165.12% from $52.09M to -$33.92M, earnings per share declined from $0.2169 to -$0.1361, and operating cash flow declined 127.53% from $116.35M to -$32.03M.
Gossamer Bio, Inc. (GOSS) was downgraded to E+ from D- on 11/12/2024 due to a major decline in the growth index, solvency index and valuation index. EBIT declined 165.12% from $52.09M to -$33.92M, earnings per share declined from $0.2169 to -$0.1361, and operating cash flow declined 127.53% from $116.35M to -$32.03M.
D
Sell
8/15/2024Upgraded
Gossamer Bio, Inc. (GOSS) was upgraded to D- from E+ on 8/15/2024 due to a large increase in the solvency index, valuation index and volatility index. Debt to equity declined from 7.82 to 2.44, and the quick ratio increased from 6.82 to 7.93.
Gossamer Bio, Inc. (GOSS) was upgraded to D- from E+ on 8/15/2024 due to a large increase in the solvency index, valuation index and volatility index. Debt to equity declined from 7.82 to 2.44, and the quick ratio increased from 6.82 to 7.93.
E
Sell
5/28/2024Downgrade
Gossamer Bio, Inc. (GOSS) was downgraded to E+ from D- on 5/28/2024 due to a decline in the valuation index, solvency index and volatility index. Debt to equity increased from 3.38 to 7.82.
Gossamer Bio, Inc. (GOSS) was downgraded to E+ from D- on 5/28/2024 due to a decline in the valuation index, solvency index and volatility index. Debt to equity increased from 3.38 to 7.82.
D
Sell
4/19/2024Upgraded
Gossamer Bio, Inc. (GOSS) was upgraded to D- from E+ on 4/19/2024 due to an increase in the valuation index and total return index.
Gossamer Bio, Inc. (GOSS) was upgraded to D- from E+ on 4/19/2024 due to an increase in the valuation index and total return index.
E
Sell
3/8/2024Downgrade
Gossamer Bio, Inc. (GOSS) was downgraded to E+ from D- on 3/8/2024 due to a decline in the solvency index and valuation index. Debt to equity increased from 2.05 to 3.38, and the quick ratio declined from 7.77 to 5.74.
Gossamer Bio, Inc. (GOSS) was downgraded to E+ from D- on 3/8/2024 due to a decline in the solvency index and valuation index. Debt to equity increased from 2.05 to 3.38, and the quick ratio declined from 7.77 to 5.74.
D
Sell
2/28/2024Upgraded
Gossamer Bio, Inc. (GOSS) was upgraded to D- from E+ on 2/28/2024 due to a substantial increase in the solvency index, total return index and volatility index. The quick ratio increased from 4.04 to 7.77.
Gossamer Bio, Inc. (GOSS) was upgraded to D- from E+ on 2/28/2024 due to a substantial increase in the solvency index, total return index and volatility index. The quick ratio increased from 4.04 to 7.77.
E
Sell
8/14/2023Downgrade
Gossamer Bio, Inc. (GOSS) was downgraded to E+ from D- on 8/14/2023 due to a decline in the volatility index.
Gossamer Bio, Inc. (GOSS) was downgraded to E+ from D- on 8/14/2023 due to a decline in the volatility index.
D
Sell
8/8/2023Upgraded
Gossamer Bio, Inc. (GOSS) was upgraded to D- from E+ on 8/8/2023 due to an increase in the volatility index and total return index.
Gossamer Bio, Inc. (GOSS) was upgraded to D- from E+ on 8/8/2023 due to an increase in the volatility index and total return index.
E
Sell
3/14/2023Downgrade
Gossamer Bio, Inc. (GOSS) was downgraded to E+ from D on 3/14/2023 due to a decline in the total return index and volatility index.
Gossamer Bio, Inc. (GOSS) was downgraded to E+ from D on 3/14/2023 due to a decline in the total return index and volatility index.
D
Sell
2/9/2023Upgraded
Gossamer Bio, Inc. (GOSS) was upgraded to D from E+ on 02/09/2023.
Gossamer Bio, Inc. (GOSS) was upgraded to D from E+ on 02/09/2023.
E
Sell
2/8/2023Downgrade
Gossamer Bio, Inc. (GOSS) was downgraded to E+ from D on 2/8/2023 due to a significant decline in the total return index and volatility index.
Gossamer Bio, Inc. (GOSS) was downgraded to E+ from D on 2/8/2023 due to a significant decline in the total return index and volatility index.
D
Sell
11/7/2022Downgrade
Gossamer Bio, Inc. (GOSS) was downgraded to D from D+ on 11/7/2022 due to a decline in the valuation index.
Gossamer Bio, Inc. (GOSS) was downgraded to D from D+ on 11/7/2022 due to a decline in the valuation index.
D
Sell
8/31/2022Upgraded
Gossamer Bio, Inc. (GOSS) was upgraded to D+ from D on 8/31/2022 due to a large increase in the total return index, growth index and valuation index. Operating cash flow increased 8.71% from -$53.48M to -$48.82M, earnings per share increased from -$0.7614 to -$0.7365, and EBIT increased 0.86% from -$54.32M to -$53.86M.
Gossamer Bio, Inc. (GOSS) was upgraded to D+ from D on 8/31/2022 due to a large increase in the total return index, growth index and valuation index. Operating cash flow increased 8.71% from -$53.48M to -$48.82M, earnings per share increased from -$0.7614 to -$0.7365, and EBIT increased 0.86% from -$54.32M to -$53.86M.
D
Sell
8/3/2022Upgraded
Gossamer Bio, Inc. (GOSS) was upgraded to D from D- on 8/3/2022 due to an increase in the total return index and volatility index.
Gossamer Bio, Inc. (GOSS) was upgraded to D from D- on 8/3/2022 due to an increase in the total return index and volatility index.
D
Sell
5/31/2022Upgraded
Gossamer Bio, Inc. (GOSS) was upgraded to D- from E+ on 05/31/2022.
Gossamer Bio, Inc. (GOSS) was upgraded to D- from E+ on 05/31/2022.
E
Sell
5/13/2022Downgrade
Gossamer Bio, Inc. (GOSS) was downgraded to E+ from D- on 05/13/2022.
Gossamer Bio, Inc. (GOSS) was downgraded to E+ from D- on 05/13/2022.
D
Sell
5/11/2022Downgrade
Gossamer Bio, Inc. (GOSS) was downgraded to D- from D on 5/11/2022 due to a noticeable decline in the solvency index, growth index and valuation index. Debt to equity increased from 1.5 to 7.53, operating cash flow declined 32.03% from -$40.51M to -$53.48M, and EBIT declined 5.18% from -$51.65M to -$54.32M.
Gossamer Bio, Inc. (GOSS) was downgraded to D- from D on 5/11/2022 due to a noticeable decline in the solvency index, growth index and valuation index. Debt to equity increased from 1.5 to 7.53, operating cash flow declined 32.03% from -$40.51M to -$53.48M, and EBIT declined 5.18% from -$51.65M to -$54.32M.
D
Sell
5/4/2022Upgraded
Gossamer Bio, Inc. (GOSS) was upgraded to D from E+ on 5/4/2022 due to an increase in the valuation index.
Gossamer Bio, Inc. (GOSS) was upgraded to D from E+ on 5/4/2022 due to an increase in the valuation index.
E
Sell
5/1/2022Downgrade
Gossamer Bio, Inc. (GOSS) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index.
Gossamer Bio, Inc. (GOSS) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index.
D
Sell
4/21/2022Upgraded
Gossamer Bio, Inc. (GOSS) was upgraded to D from E+ on 4/21/2022 due to an increase in the volatility index.
Gossamer Bio, Inc. (GOSS) was upgraded to D from E+ on 4/21/2022 due to an increase in the volatility index.
E
Sell
4/20/2022Downgrade
Gossamer Bio, Inc. (GOSS) was downgraded to E+ from D on 4/20/2022 due to a decline in the volatility index, total return index and solvency index. Debt to equity increased from 1.06 to 1.5, and the quick ratio declined from 10.2 to 8.16.
Gossamer Bio, Inc. (GOSS) was downgraded to E+ from D on 4/20/2022 due to a decline in the volatility index, total return index and solvency index. Debt to equity increased from 1.06 to 1.5, and the quick ratio declined from 10.2 to 8.16.
D
Sell
11/10/2021Upgraded
Gossamer Bio, Inc. (GOSS) was upgraded to D from D- on 11/10/2021 due to an increase in the growth index and total return index. Operating cash flow increased 11.41% from -$47.45M to -$42.04M.
Gossamer Bio, Inc. (GOSS) was upgraded to D from D- on 11/10/2021 due to an increase in the growth index and total return index. Operating cash flow increased 11.41% from -$47.45M to -$42.04M.
D
Sell
11/8/2021Downgrade
Gossamer Bio, Inc. (GOSS) was downgraded to D- from D on 11/8/2021 due to a decline in the solvency index, valuation index and growth index. Debt to equity increased from 0.65 to 0.81, the quick ratio declined from 15.4 to 13.54, and EBIT declined 4.53% from -$53.17M to -$55.58M.
Gossamer Bio, Inc. (GOSS) was downgraded to D- from D on 11/8/2021 due to a decline in the solvency index, valuation index and growth index. Debt to equity increased from 0.65 to 0.81, the quick ratio declined from 15.4 to 13.54, and EBIT declined 4.53% from -$53.17M to -$55.58M.
D
Sell
7/14/2021Upgraded
Gossamer Bio, Inc. (GOSS) was upgraded to D from D- on 7/14/2021 due to an increase in the volatility index and total return index.
Gossamer Bio, Inc. (GOSS) was upgraded to D from D- on 7/14/2021 due to an increase in the volatility index and total return index.
D
Sell
6/28/2021Downgrade
Gossamer Bio, Inc. (GOSS) was downgraded to D- from D on 6/28/2021 due to a decline in the volatility index and total return index.
Gossamer Bio, Inc. (GOSS) was downgraded to D- from D on 6/28/2021 due to a decline in the volatility index and total return index.
D
Sell
5/11/2021Upgraded
Gossamer Bio, Inc. (GOSS) was upgraded to D from D- on 5/11/2021 due to an increase in the growth index, volatility index and valuation index. Earnings per share increased from -$0.8824 to -$0.7779, and EBIT increased 2.95% from -$54.79M to -$53.17M.
Gossamer Bio, Inc. (GOSS) was upgraded to D from D- on 5/11/2021 due to an increase in the growth index, volatility index and valuation index. Earnings per share increased from -$0.8824 to -$0.7779, and EBIT increased 2.95% from -$54.79M to -$53.17M.
D
Sell
2/26/2021Downgrade
Gossamer Bio, Inc. (GOSS) was downgraded to D- from D on 2/26/2021 due to a noticeable decline in the growth index. Earnings per share declined from -$0.8002 to -$0.8824, and EBIT declined 2.8% from -$53.29M to -$54.79M.
Gossamer Bio, Inc. (GOSS) was downgraded to D- from D on 2/26/2021 due to a noticeable decline in the growth index. Earnings per share declined from -$0.8002 to -$0.8824, and EBIT declined 2.8% from -$53.29M to -$54.79M.
D
Sell
5/13/2020Upgraded
Gossamer Bio, Inc. (GOSS) was upgraded to D from D- on 5/13/2020 due to a large increase in the growth index, total return index and volatility index. EBIT increased 3.74% from -$54.19M to -$52.16M, and earnings per share increased from -$0.8926 to -$0.8737.
Gossamer Bio, Inc. (GOSS) was upgraded to D from D- on 5/13/2020 due to a large increase in the growth index, total return index and volatility index. EBIT increased 3.74% from -$54.19M to -$52.16M, and earnings per share increased from -$0.8926 to -$0.8737.
D
Sell
5/1/2020Downgrade
Gossamer Bio, Inc. (GOSS) was downgraded to D- from D on 5/1/2020 due to a significant decline in the efficiency index, total return index and valuation index.
Gossamer Bio, Inc. (GOSS) was downgraded to D- from D on 5/1/2020 due to a significant decline in the efficiency index, total return index and valuation index.
D
Sell
3/26/2020Upgraded
Gossamer Bio, Inc. (GOSS) was upgraded to D from D- on 3/26/2020 due to a substantial increase in the efficiency index.
Gossamer Bio, Inc. (GOSS) was upgraded to D from D- on 3/26/2020 due to a substantial increase in the efficiency index.
D
Sell
2/26/2020Downgrade
Gossamer Bio, Inc. (GOSS) was downgraded to D- from D on 2/26/2020 due to a decline in the volatility index, total return index and solvency index. The quick ratio declined from 16.87 to 13.46, and debt to equity increased from 0.07 to 0.08.
Gossamer Bio, Inc. (GOSS) was downgraded to D- from D on 2/26/2020 due to a decline in the volatility index, total return index and solvency index. The quick ratio declined from 16.87 to 13.46, and debt to equity increased from 0.07 to 0.08.
D
Sell
10/29/2019Upgraded
Gossamer Bio, Inc. (GOSS) was upgraded to D from D- on 10/29/2019 due to an increase in the volatility index.
Gossamer Bio, Inc. (GOSS) was upgraded to D from D- on 10/29/2019 due to an increase in the volatility index.
D
Sell
10/2/2019Downgrade
Gossamer Bio, Inc. (GOSS) was downgraded to D- from D on 10/2/2019 due to a large decline in the volatility index and total return index.
Gossamer Bio, Inc. (GOSS) was downgraded to D- from D on 10/2/2019 due to a large decline in the volatility index and total return index.
D
Sell
8/13/2019Downgrade
Gossamer Bio, Inc. (GOSS) was downgraded to D from C- on 8/13/2019 due to a significant decline in the efficiency index, growth index and solvency index. EBIT declined 37.35% from -$33.02M to -$45.35M, net income declined 36.45% from -$32.61M to -$44.5M, and operating cash flow declined 32.53% from -$27.77M to -$36.81M.
Gossamer Bio, Inc. (GOSS) was downgraded to D from C- on 8/13/2019 due to a significant decline in the efficiency index, growth index and solvency index. EBIT declined 37.35% from -$33.02M to -$45.35M, net income declined 36.45% from -$32.61M to -$44.5M, and operating cash flow declined 32.53% from -$27.77M to -$36.81M.
C
Hold
7/26/2019Upgraded
Gossamer Bio, Inc. (GOSS) was upgraded to C- from D+ on 7/26/2019 due to an increase in the volatility index and total return index.
Gossamer Bio, Inc. (GOSS) was upgraded to C- from D+ on 7/26/2019 due to an increase in the volatility index and total return index.
D
Sell
7/8/2019Downgrade
Gossamer Bio, Inc. (GOSS) was downgraded to D+ from C- on 7/8/2019 due to a decline in the volatility index and total return index.
Gossamer Bio, Inc. (GOSS) was downgraded to D+ from C- on 7/8/2019 due to a decline in the volatility index and total return index.
C
Hold
6/18/2019Upgraded
Gossamer Bio, Inc. (GOSS) was upgraded to C- from D+ on 6/18/2019 due to a noticeable increase in the volatility index.
Gossamer Bio, Inc. (GOSS) was upgraded to C- from D+ on 6/18/2019 due to a noticeable increase in the volatility index.
D
Sell
5/31/2019Downgrade
Gossamer Bio, Inc. (GOSS) was downgraded to D+ from C- on 5/31/2019 due to a noticeable decline in the volatility index.
Gossamer Bio, Inc. (GOSS) was downgraded to D+ from C- on 5/31/2019 due to a noticeable decline in the volatility index.
C
Hold
5/16/2019Upgraded
Gossamer Bio, Inc. (GOSS) was upgraded to C- from D on 5/16/2019 due to a substantial increase in the efficiency index, growth index and volatility index. Total capital increased 125.82% from $218.3M to $492.97M, earnings per share increased from -$5.0925 to -$0.8979, and EBIT increased 17.06% from -$39.81M to -$33.02M.
Gossamer Bio, Inc. (GOSS) was upgraded to C- from D on 5/16/2019 due to a substantial increase in the efficiency index, growth index and volatility index. Total capital increased 125.82% from $218.3M to $492.97M, earnings per share increased from -$5.0925 to -$0.8979, and EBIT increased 17.06% from -$39.81M to -$33.02M.
D
Sell
5/7/2019None
Gossamer Bio, Inc. (GOSS) was downgraded to D from U on 05/07/2019.
Gossamer Bio, Inc. (GOSS) was downgraded to D from U on 05/07/2019.
NASDAQ
03/14/2025 4:00PM Eastern
Quotes delayed
